Atossa Genetics Gets Interim Safety Data from Ongoing Study

Pharmaceutical Investing

Atossa Genetics shared a batch of positive interim safety data from its Phase 1 dose escalation study on Endoxifen.

Atossa Genetics (NASDAQ:ATOS) shared a batch of positive interim safety data from its Phase 1 dose escalation study on Endoxifen.
As quoted in the press release:

Endoxifen is an active metabolite of the FDA approved drug tamoxifen, which is indicated for breast cancer and breast cancer prevention in high-risk patients. The Independent Safety Committee reviewed the blinded data generated from the first cohort receiving the oral formulation (8 subjects) and concluded that the study may advance to the next oral dosing level.
The study includes two arms: one receiving a topical formulation of Endoxifen and another receiving an oral formulation, each with three cohorts. The topical arm has been fully enrolled and dosed and the first of the three oral cohorts has now been dosed.
“Our Phase 1 study of our proprietary Endoxifen is progressing quickly and as planned,” stated Dr. Steve Quay, CEO and President. “This interim safety determination allows us to proceed to the next dosing level and, based on the progress to date, we expect to complete enrollment in the next six weeks.”

Click here to read the full press release.

Source: www.marketwired.com

The Conversation (0)
×